Lonza, the world's largest contract development and manufacturing organization (CDMO), announced today the nomination of Stephen Fry as an Independent Member of its Board of Directors. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Fry will also be appointed to the People and Governance Committee and the Audit and Compliance Committee.
Fry brings over three decades of pharmaceutical industry experience, having spent his entire career at Eli Lilly and Company. There, he held a broad range of international, operational, and executive leadership roles, ultimately serving as Executive Vice President and Chief Human Resources Officer for 12 years. In this role, he led large-scale organizational transformation, shaped high-performance cultures, and helped navigate the company through significant change. Fry also serves as a Member of the Board of Trustees at the University of Indianapolis (US).
Jean-Marc Huet, Chairman of the Board at Lonza, commented: "The Board of Directors extends its warmest congratulations to Stephen for his nomination to the Board. Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level."
The nomination comes as Lonza continues to strengthen its leadership team to support its growth strategy. The company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. With approximately 20,000 colleagues working across five continents, Lonza partners with pharma and biotech companies to turn breakthrough innovations into viable therapies.
Fry's appointment is seen as a strategic move to enhance Lonza's board capabilities in organizational development and talent management, critical areas as the company scales its operations. His experience in fostering high-performance cultures aligns with Lonza's ambition to attract and retain world-leading talent. For more information about Lonza, visit www.lonza.com.
This nomination underscores the importance of strong governance and people strategy in the rapidly evolving healthcare industry. Lonza's focus on embedding a performance culture is essential for maintaining its competitive edge and delivering value to its clients and patients worldwide.
